Published in ACS Med Chem Lett on October 16, 2013
Structure-Based Design of Inhibitors of Protein-Protein Interactions: Mimicking Peptide Binding Epitopes. Angew Chem Int Ed Engl (2015) 1.17
Dual-purpose linker for alpha helix stabilization and imaging agent conjugation to glucagon-like peptide-1 receptor ligands. Bioconjug Chem (2015) 0.80
Influence of macrocyclization on allosteric, juxtamembrane-derived, stapled peptide inhibitors of the epidermal growth factor receptor (EGFR). Org Lett (2014) 0.77
Getting across the cell membrane: an overview for small molecules, peptides, and proteins. Methods Mol Biol (2015) 0.76
Maternal Fructose Exposure Programs Metabolic Syndrome-Associated Bladder Overactivity in Young Adult Offspring. Sci Rep (2016) 0.75
Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science (2004) 7.63
Direct inhibition of the NOTCH transcription factor complex. Nature (2009) 4.82
Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med (2001) 2.81
Dual role of proapoptotic BAD in insulin secretion and beta cell survival. Nat Med (2008) 2.78
Isolation from porcine-intestinal wall of a vasoactive octacosapeptide related to secretin and to glucagon. Eur J Biochem (1972) 2.59
Crystal structure of the incretin-bound extracellular domain of a G protein-coupled receptor. Proc Natl Acad Sci U S A (2007) 2.13
Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide. Neuron (1992) 1.90
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol (2009) 1.79
Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1. Br J Pharmacol (2012) 1.64
Stapled peptides for intracellular drug targets. Methods Enzymol (2012) 1.61
Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic. Proc Natl Acad Sci U S A (2010) 1.51
Stabilizing the pro-apoptotic BimBH3 helix (BimSAHB) does not necessarily enhance affinity or biological activity. ACS Chem Biol (2012) 1.50
Synthesis of all-hydrocarbon stapled α-helical peptides by ring-closing olefin metathesis. Nat Protoc (2011) 1.44
The VIP2 receptor: molecular characterisation of a cDNA encoding a novel receptor for vasoactive intestinal peptide. FEBS Lett (1993) 1.41
Ring-closing metathesis of olefinic peptides: design, synthesis, and structural characterization of macrocyclic helical peptides. J Org Chem (2001) 1.34
Structure of the stapled p53 peptide bound to Mdm2. J Am Chem Soc (2011) 1.30
A perfluoroaryl-cysteine S(N)Ar chemistry approach to unprotected peptide stapling. J Am Chem Soc (2013) 1.23
Cloning and functional characterization of a third pituitary adenylate cyclase-activating polypeptide receptor subtype expressed in insulin-secreting cells. Proc Natl Acad Sci U S A (1994) 1.12
Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation. FASEB J (2003) 1.12
Vasoactive intestinal peptide in man: pharmacokinetics, metabolic and circulatory effects. Gut (1978) 1.09
Development of selective agonists and antagonists for the human vasoactive intestinal polypeptide VPAC(2) receptor. Peptides (2000) 1.08
Role of VIP and PACAP in islet function. Peptides (2007) 1.07
A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal: a potential therapy for type 2 diabetes. Diabetes (2002) 1.02
Vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating peptide receptor 2 deficiency in mice results in growth retardation and increased basal metabolic rate. Endocrinology (2002) 0.99
Development of potent glucagon-like peptide-1 agonists with high enzyme stability via introduction of multiple lactam bridges. J Med Chem (2010) 0.99
Neuroprotective strategy for Alzheimer disease: intranasal administration of a fatty neuropeptide. Proc Natl Acad Sci U S A (1996) 0.99
Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease. Brain Res (2000) 0.98
Stabilization of vasoactive intestinal peptide by lipids. J Pharmacol Exp Ther (1998) 0.86
Generation of highly selective VPAC2 receptor agonists by high throughput mutagenesis of vasoactive intestinal peptide and pituitary adenylate cyclase-activating peptide. J Biol Chem (2003) 0.83
Comparative effects of PACAP and VIP on pancreatic endocrine secretions and vascular resistance in rat. Br J Pharmacol (1996) 0.81
All-hydrocarbon stapled peptides as Synthetic Cell-Accessible Mini-Proteins. Drug Discov Today Technol (2012) 0.80